Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2023-03-23 Capital/Financing Update
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - CYC 7 pages 29.4KB
Capital/Financing Update Classification · 95% confidence The document is an application for quotation of securities issued under an employee incentive scheme by Cyclopharm Limited. It details the number of securities to be quoted, issue price, issue date, and confirms that these securities will rank equally with existing securities. The document is a formal announcement related to the listing of new securities on the ASX (Australian Securities Exchange). It does not contain financial statements, management discussion, or detailed financial results. It is not an annual or interim report, earnings release, or management report. It is also not a proxy, voting result, or governance document. The content fits the category of a capital/financing update as it relates to the issuance and quotation of new securities, which affects the company's capital structure. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a confident classification.
2023-03-23 English
Date of Annual General Meeting 1 page 77.7KB
AGM Information Classification · 95% confidence The document is an announcement from Cyclopharm Limited regarding the date of their upcoming Annual General Meeting (AGM) and the closing date for director nominations. It references the ASX Listing Rule 3.13.1 and provides logistical details about the AGM and director nominations. There is no financial data, no detailed report content, and the document is relatively short (2659 characters). It is clearly an announcement related to the AGM but not the AGM materials or presentations themselves. Therefore, it fits the category of AGM Information (AGM-R) as it pertains to the AGM event details and director nominations, which are typical AGM-related announcements.
2023-03-14 English
Dividend/Distribution - CYC 4 pages 25.0KB
Notice of Dividend Amount Classification · 100% confidence The document is a notification of dividend/distribution for Cyclopharm Limited, detailing the dividend amount, ex-date, record date, and payment date. It provides specific dividend payment information but does not contain comprehensive financial statements or analysis. The document is an announcement of dividend details rather than a full financial report. Therefore, it fits the category of Notice of Dividend Amount (DIV). The document length is 4019 characters, which is consistent with a detailed dividend announcement rather than a full report.
2023-02-19 English
Preliminary Final Report 70 pages 556.7KB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E' and is a Preliminary Final Report for the year ended 31 December 2022 for Cyclopharm Limited. It contains detailed financial results, including revenues, losses, dividends, and a managing director's review discussing financial performance, operations, and strategy deliverables. The document includes financial statements references (statement of financial performance, position, cash flows, retained earnings) and commentary on results. It also mentions the accounts are in the process of being audited. The length is substantial (15,000 characters), and the content is comprehensive, covering a full fiscal year. Appendix 4E is an Australian Securities Exchange (ASX) form used for preliminary final reports, which are equivalent to annual reports but typically shorter and focused on financial results and commentary. Given the detailed financial data and annual period coverage, this document fits best as an Annual Report (10-K equivalent) rather than a mere announcement or regulatory filing. It is not a short announcement or certification, nor is it a quarterly or interim report. Therefore, the appropriate classification is Annual Report (10-K). FY 2022
2023-02-19 English
CYC Results Summary 4 pages 166.9KB
Annual Report Classification · 95% confidence The document is a detailed announcement of Cyclopharm Limited's full year financial results for the year ending 31 December 2022. It includes comprehensive financial data such as sales revenue, profit/loss figures, cash balances, and segment revenue breakdowns. It also discusses operational highlights, regulatory approval processes, capital management, and outlook for the company. The document is dated 20 February 2023 and is addressed to the Australian Securities Exchange, indicating it is a formal financial disclosure. The content is consistent with a full annual financial report rather than a brief earnings release or a simple announcement. The length (over 13,000 characters) and the inclusion of detailed financial summaries and management commentary support classification as an Annual Report (10-K equivalent). There is no indication that this is merely an announcement of a report or a certification letter, so it is not RPA or RNS. Therefore, the appropriate classification is Annual Report (10-K). FY 2022
2023-02-19 English
Change of Director's Interest Notice - KBarrow 2 pages 206.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares acquired, the nature of the interest, and the date of change. The document is a formal notification of a director's personal share transactions, specifically an on-market trade of shares. There is no financial performance data, management discussion, or report content. The document length is 4051 characters, which is consistent with a detailed notice but not a full report. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2022-12-04 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.